HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients
Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis, prognosis, and follow-up. The purpose of this study was to evaluate whether serum HE4 was related to clinicopathological risk factors and outcome. Second, the role of serum HE4 and CA125 was assessed as indicator...
Saved in:
| Main Authors: | Karin Abbink, Petra LM Zusterzeel, Anneke J Geurts-Moespot, Antonius E van Herwaarden, Johanna MA Pijnenborg, Fred CGJ Sweep, Leon FAG Massuger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-02-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428318757103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Specific antitumor activity of anti-CA125 CAR-T lymphocytes against CA125-positive and CA125-negative cells
by: T. M. Kulinich, et al.
Published: (2024-07-01) -
A Dual Immunosensor Based on Optical Weak Value Amplification for Simultaneous Detection of CA125 and HE4
by: Bei Wang, et al.
Published: (2025-05-01) -
Effects of GnRH Agonist and Dienogest in Combination on HE4 and CA125 Levels in Patients with Adenomyosis and Adenomyoma: A Prospective Cohort Study
by: DongGe Wang, et al.
Published: (2023-07-01) -
Tumor marker CA-125 in adnexal inflammatory tumors
by: Nikolić Branka, et al.
Published: (2006-01-01) -
The Value of CA125 and CA19-9 in the Diagnosis of Stage Ⅲ and Ⅳ Endometriosis
by: Wenwen Zhang, et al.
Published: (2024-02-01)